共 179 条
[1]
Teleanu RI, Preda MD, Niculescu AG., Current Strategies to Enhance Delivery of Drugs across the Blood-Brain Barrier, Pharmaceutics, 14, 5, (2022)
[2]
Amin ND, Pasca SP., Building Models of Brain Disorders with Three-Dimensional Organoids, Neuron, 100, 2, pp. 389-405, (2018)
[3]
Andjelkovic AV, Stamatovic SM, Phillips CM, Martinez-Revollar G, Keep RF., Modeling blood-brain barrier pathology in cerebrovascular disease in vitro: current and future paradigms, Fluids Barriers CNS, 17, 1, (2020)
[4]
Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV., Blood-Brain Barrier: from Physiology to Disease and Back, Physiol Rev, 99, 1, pp. 21-78, (2019)
[5]
Lingineni K, Belekar V, Tangadpalliwar SR, Garg P., The role of multidrug resistance protein (MRP-1) as an active efflux transporter on blood– brain barrier (BBB) permeability, Mol Diver, 21, 2, pp. 355-365, (2017)
[6]
Naqvi S, Panghal A, Flora SJS., Nanotechnology: a Promising Approach for Delivery of Neuroprotective Drugs, Front Neurosci, 14, (2020)
[7]
Hersh AM, Alomari S, Tyler BM., Crossing the Blood-Brain Barrier: advances in Nanoparticle Technology for Drug Delivery in Neuro-Oncology, Int J Mol Sci, 23, 8, (2022)
[8]
Teixeira MI, Lopes CM, Amaral MH, Costa PC., Surface-modified lipid nanocarriers for crossing the blood-brain barrier (BBB): a current overview of active targeting in brain diseases, Colloids Surf B, 221, (2023)
[9]
Cullis PR, Hope MJ., Lipid Nanoparticle Systems for Enabling Gene Therapies, Mol Ther, 25, 7, pp. 1467-1475, (2017)
[10]
Sato Y, Okuyama T., Novel Enzyme Replacement Therapies for Neuropathic Mucopolysaccharidoses, Int J Mol Sci, 21, 2, (2020)